What Is an Automated Insulin Delivery System?
An Automated Insulin Delivery (AID) system — sometimes called an artificial pancreas — combines three components working together: a continuous glucose monitor (CGM) that reads blood sugar every few minutes, an insulin pump that delivers insulin under the skin, and a control algorithm that automatically calculates and adjusts how much insulin to deliver based on real-time glucose levels.
The result is a closed-loop system that mimics what a healthy pancreas does automatically — raising or lowering insulin delivery in response to blood sugar changes, including overnight while you sleep.
How AID Systems Work
In a traditional insulin regimen, the patient decides when and how much insulin to inject based on a glucose reading and meal estimate. AID systems automate most of this. The algorithm processes CGM data continuously and does one or more of the following:
- Increases insulin (automated correction bolus) when glucose trends high
- Suspends or reduces insulin when glucose trends low — preventing hypoglycemia
- Maintains a stable basal rate adjusted to your individual glucose patterns over time
The user still initiates a meal bolus before eating (in most current systems), but the algorithm handles all basal adjustments automatically. Some next-generation systems are working toward fully automated meal detection as well.
AID Systems and Type 2 Diabetes
AID technology was developed primarily for Type 1 diabetes, where the pancreas produces no insulin at all. For people with Type 1, AID systems have been transformative — dramatically improving time in range, reducing hypoglycemia, and removing much of the cognitive burden of constant glucose management.
For people with Type 2 diabetes who use insulin, AID systems offer many of the same benefits. Key differences to understand:
| Factor | Type 1 | Type 2 (insulin-using) |
|---|---|---|
| Endogenous insulin | None | Variable — some beta cell function often remains |
| Insulin sensitivity | Typically higher (more responsive to insulin) | Often lower (insulin resistance present) |
| Algorithm complexity | Well-validated across large populations | More variable; algorithms still being optimized for T2D |
| Current FDA approvals | Multiple systems approved (Omnipod 5, Tandem Control-IQ, Medtronic 780G) | T1D-labeled but used off-label in T2D; dedicated T2D AID trials ongoing |
Clinical studies in insulin-using T2D patients show meaningful A1C reductions and hypoglycemia reductions with AID systems. The evidence base is growing rapidly as the technology is studied in broader populations.
Benefits of AID for Insulin-Using People with Type 2 Diabetes
- Reduced cognitive burden — the system handles minute-to-minute insulin adjustments automatically
- Improved time in range — more hours per day with glucose in the healthy 70–180 mg/dL range
- Fewer hypoglycemic episodes — predictive low-glucose suspend prevents dangerous drops
- Better overnight control — the algorithm adjusts insulin while you sleep, addressing the dawn phenomenon and overnight variability
- Lower A1C — consistent evidence of A1C reduction in clinical trials
Who Is a Candidate?
AID systems are currently most relevant for people with Type 2 diabetes who:
- Use insulin (basal, basal-bolus, or intensive regimens)
- Have difficulty achieving their A1C target despite medication adherence
- Experience hypoglycemia or hypoglycemia unawareness
- Are comfortable using technology or are willing to learn
If you use insulin for Type 2 diabetes, ask your endocrinologist or diabetes care specialist whether an AID system — or at minimum a standalone CGM — might be appropriate for your situation. Coverage is improving as the evidence base grows.
Related Articles
- Continuous Glucose Monitors (CGMs) for Type 2 Diabetes: What They Do and How to Get One
- Artificial Intelligence and Type 2 Diabetes: From Prevention to Daily Management
This article is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before making changes to your diabetes management plan.
Sources & Further Reading
- ADA Standards of Care: Diabetes Technology (2024) — American Diabetes Association
- Artificial Pancreas Device System — U.S. Food & Drug Administration
- Continuous Glucose Monitoring — NIDDK
- CGMs for People with Diabetes — diabetes.org
